While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in the tumor microenvironment.
Star power eclipses science in obesity discussions on social media
Celebrity tweets about obesity and weight loss attract far more positive engagement than those from medical authorities, underscoring their potential as powerful health messengers.
December 2, 2024